Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema
Bressler S, Barve A, Ganapathi P, Beckmann K, Apte R, Marcus D, Baumane K, Agarwal S, Oleksy P, Reichstein D, Patel S, Ernest J, Dégi R, Gupta V, Kishino G, Kamei M, Loganathan S, Chaudhry N, Reichstein D, Tabassian A, Fine H, Sjaarda R, Marcus D, Barakat M, Dugel, P, Eichenbaum D, Dessouki A, Berger A, Angle B, Chang M, Patel S, Brown D, Thach A, Baker C, Gordon A, Mansour S, Fox G, Alfaro D, Davies J, Ghorayeb G, Stoller G, Johnson T, Nemcansky J, Rehak J, Studnicka J, Ernest J, Korda V, Veith M, Krzyzanek D, Kalvodova B, Stodulka P, Feltgen N, PD K, Grisanti S, Gamulescu M, Kellner U, Sekundo W, Dahlke C, Zeitz O, Baumane K, Laganovska G, Ozolina S, Vajas A, Seres A, Tsorbatzoglou A, Radnoti J, Kiss K, Gombos K, Degi R, Varsanyi B, Kerenyi A, Noge S, Muramatsu T, Kaga T, Oh H, Watanabe M, Oshima Y, Fujita H, Kishino G, Hanemoto T, Murata K, Kitaoka T, Saito I, Tanabe T, Ebihara N, Imaizumi H, Ishii K, Kamei M, Furuta M, Ojima A, Sawada O, Kawasaki T, Otake H, Doi N, Abe, K, Matsuda S, Kobayashi N, Yoshizumi Y, Budzinskaya M, Lebedev O, Eremina A, Zolotarev A, Izmaylov A, Samoylov A, Astakhov S, Astakhov Y, Shkvorchenko D, Narayanan R, Agarwal K, Rahul S, Natesh S, Gupta V, Panchal B, Kaza H, K M, Agrawal V, Elhence A, Behera U, Raj L, Mazumdar S, Kannan N, Yadav N, Vohra R, Aggarwal S, Sonawane A, Saravanan V, Chauhan R, Fluder E, Nawrocki J, Wylegala E, Zalewski D, Oleksy P, Borcz E. Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema. JAMA Ophthalmology 2024, 142: 952-960. PMID: 39264599, PMCID: PMC11393752, DOI: 10.1001/jamaophthalmol.2024.3458.Peer-Reviewed Original ResearchBest-corrected visual acuityDiabetic macular edemaCentral subfield thicknessEarly Treatment Diabetic Retinopathy StudyAflibercept groupAntidrug antibodiesAdverse eventsWeek 8Aflibercept armMacular edemaIncidence of treatment-emergent adverse eventsPrimary outcomeBaseline BCVA letter scoreTreatment Diabetic Retinopathy StudyTreatment-emergent adverse eventsIncidence of adverse eventsConsecutive intravitreal injectionsDiabetic Retinopathy StudyRandomized clinical trialsType 2 diabetesStudy eyesSubfield thicknessDouble-MaskedIntravitreal injectionRetinopathy Study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply